Collaborative Clinical Cancer Trials Conference  
between the US and Japan in Karuizawa  
Recent Results and Future Directions of Common Arm Trials

~Final Program~

Date: September 7–8, 2007  
Location: Kajima no Mori Hall, Hotel Kajima no Mori, Nagano, Japan

September 7(Fri), 2007
12:30
Opening remarks
Dr. Hiromi Wada  
Chairman  
Japan–Multinational Trial Organization (JMTO)

Session I  
Gastric Cancer
12:40–14:00
Chairpersons:
Dr. Seiji Satoh  
Dr. Yung-Jue Bang

12:40
1) Combination therapy with S-1 and other cytotoxic drugs overcomes tumor cell resistance to fluoropyrimidines in vivo
Dr. Masakazu Fukushima  
Tokushima Research Center, Taiho Pharmaceutical Co., Ltd.  
Dr. Hiromi Wada  
Kyoto University

13:00
2) A Phase II common arm trial of neoadjuvant chemotherapy for resectable advanced gastric cancer using S-1/CDDP
Dr. Seiji Satoh  
Akita University Hospital
13:20

3) S-1 in gastric cancer chemotherapy
   Dr. Hyun C. Chung
   Yonsei University College of Medicine

13:40

4) International collaboration for gastric cancer trials
   Dr. Yung-Jue Bang
   Seoul National University Hospital

Session II
Endoscopic Study for Lung Cancer
14:00–14:40

Chairpersons:
   Dr. Thomas G. Sutedja
   Dr. Seiki Hasegawa

14:00

1) Evaluation of mediastinal nodal metastasis with endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) in operable lung cancer patients
   Dr. Fumihiro Tanaka
   Hyogo College of Medicine

14:20

2) Minimal invasive T and N working concepts
   Dr. Thomas G. Sutedja
   VU University Academic Medical Center
Session III
Clinical Trials
14:40–15:40

Chairpersons:
Dr. John J. Crowley
Dr. Satoshi Teramukai

14:40
1) Issues in the analysis of molecular epidemiologic data
Dr. Mary W. Redman
Fred Hutchinson Cancer Research Center

15:00
2) Clinical trial designs for targeted agents
Dr. John J. Crowley
Cancer Research And Biostatistics (CRAB)

15:20
3) Perspective on Lung Cancer Management in Japan
Dr. Ryosuke Tsuchiya
National Cancer Center Hospital

15:40–15:50  -Coffee Break-

Session IV
Non-Small Cell Lung Cancer – I and Small Cell Lung Cancer
15:50–17:50

Chairpersons:
Dr. Tetsuya Mitsudomi
Dr. Fumihiro Tanaka
15:50

1) Mutations of the EGFR or related genes and targeted therapy of lung cancer
   Dr. Tetsuya Mitsudomi
   Aichi Cancer Center Hospital

16:10

2) Prevalence of EGFR gene mutations on surgical specimens.
   Experience in Kyoto University Hospital
   Dr. Makoto Sonobe
   Kyoto University Hospital

16:30

3) A phase II trial of pre-operative chemoradiotherapy followed by
   surgical resection in patients with superior sulcus non-small cell lung
   cancers: report of a Japan Clinical Oncology Group trial (JCOG 9806)
   Dr. Masahiro Tsuboi
   Tokyo Medical University & Hospital

16:50

4) Surgical treatment of Pancoast tumor —Surgical approach with
   combination of open thoracotomy and VATS—
   Dr. Seiki Hasegawa
   Hyogo College of Medicine

17:10

5) International randomized study to compare Cyberknife Stereotact Radiosurgery
   with surgical resection in stage I non-small cell lung cancer
   (Lung Cancer STARS Trial)
   Dr. Jack A. Roth
   The University of Texas MD Anderson Cancer Center

17:30

6) Current status and future directions of treatment for relapsed small-cell
   lung cancer (SCLC)
   Dr. Koichi Goto
   National Cancer Center Hospital East
Session V

Key Note Address

17:50–18:10

Chairperson:

Dr. Hiromi Wada

17:50

Possibility for joint US–Japan global trials

Dr. Nagahiro Saijo

National Cancer Center Hospital East

19:00–21:00 –Banquet–

September 8(Sat), 2007

Session VI

8:00–10:00

Chairpersons:

Dr. David R. Gandara

Dr. Masaaki Kawahara

1) Common Arm Trials (CATs) in Japan and the US

8:00

1A) Rationale for Common Arm Studies

Dr. David R. Gandara

University of California Davis Cancer Center

8:10

1B) The four-arm cooperative study (FACS) for advanced non–small cell lung cancer

Dr. Kaoru Kubota

National Cancer Center Hospital East
8:30
1) JMTTO LC00-03 Trial including QOL
   Dr. Masaaki Kawahara
   Nat’l Hospital Org. Kinki-chuo Chest Medical Center

8:50
2) Pharmacogenomic analysis of Japan-SWOG common arm study in advanced stage Non-Small Cell Lung Cancer (NSCLC)
   Dr. Philip C. Mack
   University of California Davis Cancer Center

9:10
3) Common arm trials in the US and Japan
   Dr. David R. Gandara
   University of California Davis Cancer Center

9:20
4) International trials for non-small cell lung cancer in Japan
   Dr. Masahiro Fukuoka
   Sakai Hospital, Kinki University School of Medicine

9:40
5) Newer clinical trial infrastructure and paradigm in Japan—The role of the Translational Research Informatics Center
   Dr. Masanori Fukushima
   Translational Research Center, Kyoto University & Translational Research Informatics Center, Kobe

10:00-10:10 —Coffee Break—
Session VII
Non-small Cell Lung Cancer - III
10:10–10:50
Chairpersons:
Dr. Yukito Ichinose
Dr. Kaoru Kubota

10:10
1) Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small-cell lung cancer
   Dr. Shinji Atagi
   Nat’l Hospital Org, Kinki-chuo Chest Medical Center

10:30
2) Recent results and new trends of neoadjuvant and adjuvant chemotherapy for early stage NSCLC in Japan
   Dr. Yukito Ichinose
   National Kyushu Cancer Center

Session VIII
Small Cell Lung Cancer -LD -
10:50–11:30
Chairpersons:
Dr. Primo N. Lara, Jr.
Dr. Yasushi Nagata

10:50
1) A Phase II study of accelerated high dose thoracic irradiation with concurrent chemoradiotherapy for patients with LD SCLC as a common arm trial of the US trial
   Dr. Yasushi Nagata
   Graduate School of Medicine, Kyoto University
11:10
2) Recent JCOG trials of combined modality treatment for limited small-cell lung cancer
   Dr. Kaoru Kubota
   National Cancer Center Hospital East

11:30–12:30 –Lunch–

Session IX
Small Cell Lung Cancer –ED–
12:30–13:10
   Chairpersons:
   Dr. Primo N. Lara, Jr.
   Dr. Tadashi Mio

12:30
1) Recent trials of chemotherapy for extensive small cell lung cancer in the JMTO
   Dr. Tadashi Mio
   Graduate School of Medicine, Kyoto University

12:50
2) Cisplatin (Cis)/etoposide (VP16) vs. cis/irinotecan (CPT11) in extensive stage small cell lung cancer (E-SCLC): pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124
   Dr. Primo N. Lara, Jr.
   University of California Davis Cancer Center

Session X
Prognostic Index of Ovarian Cancer and Ethnicity, Gender or Other Factors for the Innovating Therapy of Lung Cancer
13:10–14:20
   Chairpersons:
   Dr. Philip C. Mack
   Dr. Tadashi Mio
13:10
1) PIEPOC: A New Prognostic Index for Advanced Epithelial Ovarian Cancer—JMTO OC01–01
   Dr. Satoshi Teramukai
   Kyoto University Hospital

13:30
2) Significant influence of smoking status and gender on the clinical outcome in the patients with non–small cell lung cancer:
   A comprehensive analysis of the 25554 Japanese patients
   Dr. Tomoya Kawaguchi
   Nat’l Hospital Org. Kinki-chuo Chest Medical Center

13:50
3) S0424: Molecular Epidemiology in Women and Men, Smokers and Never Smokers with NSCLC
   Dr. David R. Gandara
   Southwest Oncology Group(SWOG)

14:10
Closing Remarks
   Dr. Masaaki Kawahara
   Executive Director
   Japan–Multinational Trial Organization (JMTO)